The abstract is read at the publisher; the summary is JClub's.
Epigenetic priming with entinostat and immune checkpoint blockade enhances anti-tumor responses in metastatic breast cancer models by rewiring the tumor microenvironment.
- Why it matters: Limited efficacy of immune checkpoint blockade in metastatic breast cancer is partly due to suppressive myeloid and stromal cells in the tumor microenvironment, necessitating strategies to overcome resistance.
- What they did: Gonzalez and colleagues used single-cell transcriptomics, spatial proteomics, functional immunology, and mathematical modeling to analyze how combined treatment with entinostat and anti-PD-1/anti-CTLA-4 sensitizes refractory tumors in mouse models and validates findings in patient biospecimens.
- The result: The study shows that effective tumor eradication requires simultaneous modulation of T-cell activation and myeloid suppression, enabling more comprehensive strategies to improve treatment outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.